Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

PHASE3CompletedINTERVENTIONAL
Enrollment

393

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions
Asthma
Interventions
DRUG

Dupilumab SAR231893 (REGN668)

"Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous"

Trial Locations (132)

2317

Investigational Site Number :032004, Buenos Aires

4000

Investigational Site Number :032009, San Miguel de Tucumán

4071

Investigational Site Number :710006, Durban

7505

Investigational Site Number :710011, Cape Town

7531

Investigational Site Number :710001, Cape Town

7700

Investigational Site Number :710091, Cape Town

Investigational Site Number :710092, Cape Town

9000

Investigational Site Number :056003, Ghent

9400

Investigational Site Number :710009, Winnie Mandela

10787

Investigational Site Number :276006, Berlin

13015

Investigational Site Number :250001, Marseille

15241

Investigational Site Number :840091, Pittsburgh

15562

Investigational Site Number :276005, Rüdersdorf

19140

Investigational Site Number :840067, Philadelphia

20815

Investigational Site Number :840052, Chevy Chase

20878

Investigational Site Number :840073, Gaithersburg

22030

Investigational Site Number :840059, Fairfax

22927

Investigational Site Number :276011, Großhansdorf

27103

Investigational Site Number :840004, Papillion

27262

Investigational Site Number :840907, High Point

28277

Investigational Site Number :840126, Charlotte

29609

Investigational Site Number :250009, Brest

34239

Investigational Site Number :840055, Sarasota

34295

Investigational Site Number :250002, Montpellier

34761

Investigational Site Number :840115, Ocoee

41017

Investigational Site Number :840032, Fort Mitchell

43617

Investigational Site Number :840942, Toledo

44093

Investigational Site Number :250005, Nantes

55402

Investigational Site Number :840018, Minneapolis

56068

Investigational Site Number :276009, Koblenz

59037

Investigational Site Number :250010, Lille

60596

Investigational Site Number :276010, Frankfurt am Main

63141

Investigational Site Number :840102, St Louis

67091

Investigational Site Number :250008, Strasbourg

69317

Investigational Site Number :250006, Lyon

72209

Investigational Site Number :840132, Little Rock

75013

Investigational Site Number :840070, Allen

75231

Investigational Site Number :840023, Dallas

76100

Investigational Site Number :376002, Rehovot

76109

Investigational Site Number :840922, Fort Worth

76244

Investigational Site Number :840027, Fort Worth

77429

Investigational Site Number :840124, Cypress

78229

Investigational Site Number :840008, San Antonio

79109

Investigational Site Number :840062, Amarillo

80206

Investigational Site Number :840403, Denver

80246

Investigational Site Number :840130, Denver

83301

Investigational Site Number :840079, Twin Falls

84020

Investigational Site Number :840035, Draper

84107

Investigational Site Number :840077, Murray

85234

Investigational Site Number :840099, Gilbert

85248

Investigational Site Number :840087, Scottsdale

85721

Investigational Site Number :840402, Tucson

95117

Investigational Site Number :840121, San Jose

98225

Investigational Site Number :840951, Bellingham

4428164

Investigational Site Number :376001, Kfar Saba

4941492

Investigational Site Number :376005, Petah Tikva

04401

Investigational Site Number :840064, Bangor

07764

Investigational Site Number :840068, West Long Branch

05403

Investigational Site Number :840057, South Burlington

B8000JRB

Investigational Site Number :032096, Bahía Blanca

C1426ABP

Investigational Site Number :032091, Capital Federal

B1900BNN

Investigational Site Number :032002, La Plata

S2000BRH

Investigational Site Number :032006, Rosario

S2000JKR

Investigational Site Number :032005, Rosario

C1121ABE

Investigational Site Number :032003, Ciudad Autonoma Bs As

C1414AIF

Investigational Site Number :032097, Ciudad Autonoma Buenos Aires

C1414CGA

Investigational Site Number :032010, Ciudad Autonoma Buenos Aires

C1425BEN

Investigational Site Number :032001, Ciudad Autonoma Buenos Aires

T4000CHE

Investigational Site Number :032012, San Miguel de Tucumán

V5Z 1M9

Investigational Site Number :124006, Vancouver

V6Z 1Y6

Investigational Site Number :124017, Vancouver

L8N 4A6

Investigational Site Number :124016, Hamilton

K1G 6C6

Investigational Site Number :124013, Ottawa

M5T 3A9

Investigational Site Number :124002, Toronto

H4J 1C5

Investigational Site Number :124010, Montréal

H2X 1P1

Investigational Site Number :124001, Montreal

H3G 1A4

Investigational Site Number :124012, Montreal

G1V 4W2

Investigational Site Number :124014, Québec

G8T 7A1

Investigational Site Number :124007, Trois-Rivières

G1V 4G5

Investigational Site Number :124018, Québec

509-6134

Investigational Site Number :392106, Mizunami-shi

373-0807

Investigational Site Number :392043, Ota-shi

720-0001

Investigational Site Number :392021, Fukuyama-shi

734-8530

Investigational Site Number :392108, Hiroshima

0143-0076

Investigational Site Number :392164, Muroran-shi

062-8618

Investigational Site Number :392008, Sapporo

064-0804

Investigational Site Number :392034, Sapporo

053-8506

Investigational Site Number :392006, Tomakomai-shi

650-0017

Investigational Site Number :392162, Kobe

319-1113

Investigational Site Number :392020, Naka-gun

762-8550

Investigational Site Number :392011, Sakaide-shi

231-8682

Investigational Site Number :392014, Yokohama

615-8087

Investigational Site Number :392153, Kyoto

989-6183

Investigational Site Number :392170, Osaki-shi

904-2293

Investigational Site Number :392045, Uruma

596-8501

Investigational Site Number :392119, Kishiwada-shi

772-0017

Investigational Site Number :392005, Naruto-shi

103-0028

Investigational Site Number :392002, Chuo-ku

104-0031

Investigational Site Number :392112, Chuo-ku

194-0023

Investigational Site Number :392133, Machida-shi

198-0042

Investigational Site Number :392177, Ome-shi

158-0097

Investigational Site Number :392038, Setagaya-ku

142-8666

Investigational Site Number :392167, Shinagawa-ku

190-0012

Investigational Site Number :392173, Tachikawa-shi

674-0063

Investigational Site Number :392185, Akashi-shi

103-0027

Investigational Site Number :392007, Chūōku

134-0083

Investigational Site Number :392012, Edogawa-ku

583-8588

Investigational Site Number :392030, Habikino-shi

672-8064

Investigational Site Number :392004, Himeji-shi

732-0052

Investigational Site Number :392158, Hiroshima

820-8505

Investigational Site Number :392013, Iizuka-shi

372-0831

Investigational Site Number :392042, Isesaki-shi

816-0813

Investigational Site Number :392142, Kasuga-shi

187-0024

Investigational Site Number :392040, Kodaira-shi

185-0014

Investigational Site Number :392044, Kokubunji-shi

712-8064

Investigational Site Number :392010, Kurashiki-shi

612-0026

Investigational Site Number :392036, Kyoto

105-0003

Investigational Site Number :392144, Minatoku

108-8606

Investigational Site Number :392122, Minatoku

454-8509

Investigational Site Number :392163, Nagoya

589-0022

Investigational Site Number :392155, Osakasayama-shi

589-8511

Investigational Site Number :392152, Osakasayama-shi

145-0071

Investigational Site Number :392127, Ōta-ku

252-0392

Investigational Site Number :392169, Sagamihara-shi

162-8655

Investigational Site Number :392130, Shinjuku-ku

130-8587

Investigational Site Number :392165, Sumida-ku

190-0014

Investigational Site Number :392146, Tachikawa-shi

514-0125

Investigational Site Number :392029, Tsu

937-0042

Investigational Site Number :392168, Uozu-shi

901-2121

Investigational Site Number :392132, Urasoe-shi

6815 AD

Investigational Site Number :528001, Arnhem

0087

Investigational Site Number :710007, Pretoria

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT03620747 - Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) | Biotech Hunter | Biotech Hunter